What Is Bimekizumab

What bimekizumab targets and why rheumatologists consider it

Bimekizumab is a monoclonal antibody - a laboratory-engineered protein - designed to block two specific chemical signals in the immune system: IL-17A and IL-17F. In psoriatic arthritis, these two signals drive the inflammation that attacks your joints and skin. Most older biologics only block IL-17A. Bimekizumab blocks both.

You receive it as a subcutaneous injection - under the skin - once every four weeks. Your rheumatologist may consider it whether you have never tried a biologic before (called bDMARD-naive) or whether a previous biologic, specifically a TNF inhibitor, did not work well enough for you.

Knowing this helps you ask sharper questions: not just "should I try a biologic?" but "is dual IL-17 inhibition the right fit for where my disease currently is?"

Quiz

What makes bimekizumab different from most earlier biologics used in psoriatic arthritis?

02

What the Results Mean

Trial efficacy findings on joints, skin, and function in plain language

Three years of data across both trials tell a consistent story: responses that emerged in the first year held steady at year three. Here is what that looked like across the three main areas the trial measured.

Key efficacy outcomes from BE OPTIMAL and BE COMPLETE - responses maintained from year 1 to year 3

ACR50 means at least a 50% improvement in joint pain and tenderness scores - a meaningful bar. Swollen joint count resolution means no measurable swelling in the joints at all. PASI 100 means complete clearance of psoriasis skin plaques. None of these are modest targets, which is what makes the sustained rates notable.

Quiz

What does PASI 100 mean in the context of the bimekizumab trial?

Quiz

Approximately what proportion of biologic-naive patients achieved ACR50 at year 3 in the trial?

03

How the Trial Worked

Where the 3-year evidence comes from and who was studied

The evidence your rheumatologist is drawing on comes from two large Phase 3 clinical trials - BE OPTIMAL and BE COMPLETE - plus a long-term open-label extension called BE VITAL. Together they followed patients for three years and were published by Gossec et al. in 2026.

Trial	Who was enrolled	What it compared	How long
BE OPTIMAL	Patients new to biologic treatment (bDMARD-naive)	Bimekizumab vs placebo at baseline	Up to 3 years via BE VITAL extension
BE COMPLETE	Patients whose TNF inhibitor had not worked well enough (TNFi-IR)	Bimekizumab vs placebo at baseline	Up to 3 years via BE VITAL extension
BE VITAL	Completers from both trials	Open-label continuation on bimekizumab	Extended follow-up to 3-year total

All patients in the active group received bimekizumab 160 mg by subcutaneous injection every four weeks. The researchers tracked joint swelling, skin clearance, physical function, and safety at multiple points across those three years. That breadth is what makes the data meaningful for a conversation with your rheumatologist - it is not a short snapshot.

Quiz

BE COMPLETE enrolled which group of patients?

04

Timeline and What to Expect

How long bimekizumab takes to work and what response milestones look like

One of the most practical questions when starting any biologic is: how long before I know if it is working? The trial data gives a realistic frame for that conversation.

The trial measured responses at multiple points - including year 1 and year 3 - and found that the proportion of patients achieving major outcomes was already established by year 1, then held steady through year 3. This matters because it means meaningful response is not something you wait years to see; but it also means patience through the early weeks is real.

Outcome	Year 1 response rate (bDMARD-naive)	Year 3 response rate (bDMARD-naive)	Year 1 response rate (TNFi-IR)	Year 3 response rate (TNFi-IR)
ACR50 (major joint improvement)	56.1%	53.2%	50.4%	55.2%
Swollen joint count resolution	61.8%	59.5%	58.2%	59.1%
PASI 100 (full skin clearance)	64.7%	61.9%	66.2%	67.5%

What the table shows: responses established at year 1 are largely where they stay at year 3. There is no dramatic drop-off. For your own planning, expect your rheumatologist to want to review how you are responding somewhere in the first few months - before assuming it is or is not working.

Quiz

What does the year 1 to year 3 response data from the trial suggest about bimekizumab's long-term effect?

05

Safety and Side Effects

3-year safety signals from the trial to weigh benefits honestly

The trial tracked every treatment-emergent adverse event across three years - meaning any health event that occurred while on bimekizumab. The headline finding: no new safety signals appeared in years 2 or 3 that were not already seen in year 1.

The rate of adverse events was measured per 100 patient-years - a standard way of accounting for different amounts of time on treatment. In biologic-naive patients the rate was 164.2 events per 100 patient-years; in TNFi-IR patients it was 88.6. Your rheumatologist will interpret what those numbers mean for your specific situation, including any other conditions or medications you are managing.

The important point for your conversation is not the raw numbers but the pattern: consistent and stable across three years. That is the kind of predictability that allows a rheumatologist to assess long-term suitability with confidence.

Quiz

What did the 3-year trial data show about bimekizumab's safety profile over time?

Download

Questions for Your Rheumatologist

Printable question list grounded in the 3-year trial findings

Open download

07

Check Your Understanding

Short quiz to confirm you can recall and apply the key points

You have covered what bimekizumab does, how the trial was designed, what the three-year results showed across joints and skin, what to expect on the timeline, and what the safety data tells you. These questions check whether the key points have landed.

Once you have worked through them, you are ready to use the question list from the previous module in a real conversation with your rheumatologist.

Quiz

Which two cytokines does bimekizumab selectively inhibit?

Quiz